Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US Senators Urge PTO’s Vidal To Tackle Pharma Patent Thickets

Thickets Stifle Competition For Generic And Biosimilar Drugs

Jun 27 2022

• By Chloe Kent

Thicket — Patent thickets are known to delay entry of generic competitors to the market. • Source: Shutterstock

Related Content

US FDA’s Patent ‘Concerns’ Include Thickets, Product Hopping, And Evergreening

Sep 11 2021

Drug Pricing Reform: Now It Is HHS Secretary Becerra’s Turn

Jul 12 2021

US FDA, PTO Pulled Into Debate Over Patents And Drug Pricing

Feb 08 2022

I-MAK Defends ‘Patent Thicket’ Claims In Response To Thom Tillis Letter

Mar 16 2022

Senators Slam FDA And PTO For Patent ‘Oversight Gaps’

Jun 01 2022

Additional Topics

United States Intellectual Property Lobbying Generic Drugs Biosimilars BioPharmaceutical

More from Legal & IP

More from Generics Bulletin

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.